One meta-analysis showed reported benefit for IL-6 inhibitor therapy restricted to the anti-IL-6 receptor antibody preparation tocilizumab (WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, 2021). Here, IL6 is linked to COVID-19.